portfolio augmentation for a potential biologic drug rationale and pathway analysis. all (acute...

Download Portfolio augmentation for a potential biologic drug rationale and pathway analysis. ALL (Acute Lymphoblastic

Post on 22-Jul-2020

0 views

Category:

Documents

0 download

Embed Size (px)

TRANSCRIPT

  • Portfolio Augmentation for a Potential Biologic Drug

    The Excelra Approach

    The partner had a large molecule asset that was under development for blood cancer. They were interested in expanding the therapeutic potential of the molecule to solid tumours to augment the existing portfolio.

    The focus was on leveraging public gene expression data-sets from cancer patients treated with a drug candidate with similar mechanism of action. Machine-learning based predictive models were built using information on drug responsiveness and disease gene signatures.

    Predictive models were built using an iterative approach wherein patient-level and disease-level gene expression profiles were used as input data. Clustering of cancer indications was done to prioritize indications which were potentially sensitive to the treatment. Biological rationale was built was each of the prioritized indications by converging the drug mechanism of action with disease pathophysiology.

    Client Requirement

    About the Client LOCATION Europe

    THERAPEUTIC AREA Oncology

    INDUSTRY Biotech

    The Purpose

    2 months

    3 FTE

    Multiple Corroborative ML Classifiers

    Public domain patient drug response data

    Disease gene expression datasets

    Disease sub-type specific datasets

    Literature genes from other indications

    Classifier-2ML

    Bladder Cancer Cholangiocarcinoma

    Stomach Cancer TNBC_BL1

    Sensitive patient

    Resistant patient

    Classifier-1

    ML

    Perturbed genes in sensitive patient

    Predicted gene signature

    Prioritized Indications for given drug

    Disease sub type clustering

    Gene centric pathway elucidation

    Cancer patient data from client (known drug response)

    ALL Liver cancer Ovarian cancer

    AML Drug Responders Potential Responders

    TNBC

    Non-Responders

    Case Study

  • Excelra’s Contribution

    Created value for shareholders and the Board to fund future programs. Potential revenue generation >$2Bil*.

    Excelra facilitated portfolio optimization and expansion for the partner, by Prioritizing 10 oncology indications, a mix of solid & liquid tumors types.

    Determined causal gene signatures and provided a comprehensive biological

    rationale and pathway analysis.

    ALL (Acute Lymphoblastic Leukemia) determined as a top-priority indication by

    Excelra, was further confirmed by the client, that successfully

    validated our approaches.

    Portfolio enhanced for next 2 years.

    Prediction of drug-response at a

    cancer subtype level.

    Increased application of partner’s technology

    platform & external validation.

    Excelra’s Service Portfolio

    Chemistry Curation Services

    Biology Curation Services

    GOBIOM Biomarker intelligence database

    Clinical Trial Outcomes Database

    RWE & Big Data Realization

    SLR & Meta-analysis

    GOSTAR Structure Activity Relationship database

    Data

    Clinical

    Technology

    Solutions

    Discovery

    Translational

    Value Evidence

    Target Identification

    Target Dossier Services

    Data Science Driven Drug Discovery

    Biomarker Discovery

    Drug Repositioning

    Life Cycle Management

    Systems Biology Informatics

    Precision Oncology Informatics

    Clinical Pharmacology

    Outcomes Research

    Epidemiology Modelling

    Economic Modelling

    Value Evidence Communication

    Insights

    Enterprise Data Strategy

    Enterprise Cloud Ops

    Enterprise Digital Transformation

    For more information, visit https://www.excelra.com/clinical/#precision_oncology

    www.excelra.com

    About Excelra

    Excelra's data and analytics solutions empower innovation in life sciences across the value chain from discovery to market. The Excelra Edge comes from a seamless amalgamation of proprietary curated data assets, deep domain expertise and data science. The company's multifaceted teams harmonize and analyse large volumes of disparate unstructured data using cutting-edge technologies. We galvanize data-driven decisions to unlock operational efficiencies to accelerate drug discovery and development. Over the past 18 years, Excelra has been the preferred data and analytics partner to over 90 global clients, including 15 of the top 20 large Pharma.

    marketing@excelra.com

Recommended

View more >